About

Cartilago develops a proprietary regenerative medicine platform based on glucosamine peptidyl derivatives, targeting cartilage and extracellular matrix regeneration. Its lead asset, Regen NAPA, is a disease-modifying candidate for osteoarthritis designed to protect cartilage and stimulate its regeneration.

In parallel, Regen Longevity applies the same regenerative technology to dermatology and skin longevity, with potential applications in anti-aging, tissue quality and extracellular matrix preservation, supported by initial clinical proof-of-concept.

Cartilago

Area

Founded

2017